CombiGene comments on Eurostars funding

CombiGene, together with its Danish partner Zyneyro, has received welcome financial support of 8,6 million SEK from Eurostars for the continued development of the peptide COZY1, a drug candidate for the treatment of severe chronic pain conditions. BioStock reached out to CombiGene’s CEO Peter Ekolind for a comment.

Read the article from BioStock here: CombiGene comments on Eurostars funding – BioStock

Share